InnoCare's TYK2 inhibitor fadeucravacitinib met primary and secondary endpoints in a Phase 3 psoriasis trial, with a favorable safety profile. InnoCare plans to seek regulatory approval.
The FDA has approved Bristol Myers Squibb's CAR-T therapy Breyanzi for relapsed/refractory marginal zone lymphoma, while a novel multiple myeloma drug candidate DTP3 advances to Phase 2 trials after showing promising early results. Both developments represent significant progress in blood cancer treatment, with the marginal zone lymphoma approval based on a 95.5% response rate and the myeloma drug demonstrating selective cancer cell killing without toxicity.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07719855 |
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07719556 |
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) |
RECRUITING | PHASE2 |
| NCT07299019 |
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis |
RECRUITING | PHASE3 |
| NCT07272499 |
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease |
RECRUITING | PHASE2 |
| NCT07067463 |
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis |
RECRUITING | PHASE3 |
